logo-loader
Ilika PLC

Ilika plc - First Commercial Delivery to Cirtec Medical

RNS Number : 9246V
Ilika plc
10 March 2026
 

 

 

 

10 March 2026

Ilika plc

('Ilika,' the 'Company,' or the 'Group')

 

Ilika Announces Completion of First Commercial Delivery to Cirtec Medical

 

Electrode delivery signals further commercial progress

 

Ilika (AIM: IKA), the UK pioneer in solid state battery technology, announces it has successfully delivered its initial batch of commercial grade StereaxÒ electrode to Cirtec Medical (Cirtec) for Stereax M300 production.

 

In January 2026, Ilika that Cirtec had initiated the commercial electrode supply arrangement with Ilika to support product manufacturing. Ilika has now fulfilled the initial order, its first revenue-generating order from Cirtec.

 

The electrodes will be used in Stereax M300 batteries for validation and customer sampling across a wide range of active implantable medical device (AIMD) applications, including powering implanted sensors, neurostimulators, orthopaedic implants, orthodontic wearables and ophthalmology devices.

 

Shawn Martin, Vice President at Cirtec Medical, said: "Our close technical cooperation with Ilika has developed into an effective operational partnership, ensuring our customers will receive the highest quality product for integration into their devices. "

 

Graeme Purdy, CEO of Ilika, said: "This milestone demonstrates that Ilika's facility in the UK can deliver commercial-grade electrodes to support Cirtec's M300 manufacturing activities. We look forward to ramping our supply activities to meet customer demand."

 

ENDS--

 

Enquiries:

 

Ilika Plc
Graeme Purdy, Chief Executive

Jason Stewart, Chief Financial Officer

 

www.ilika.com

Via FTI Consulting

 


Cavendish Capital Markets Limited (Nomad and Broker)
Peter Lynch

Neil McDonald

 


+44 (0)131 220 9772

+44 (0)131 220 9771

 


FTI Consulting (Comms Advisors)

Ben Brewerton

Elizabeth Adams

Dwight Burden

ilika@fticonsulting.com

 

About Ilika plc

 

Ilika is a global expert in the development of solid-state battery technology for electric vehicles, medical devices and consumer appliances. The Company's pioneering next-generation technologies aim to provide scalable, affordable alternatives to conventional batteries, to industries which need to incorporate a smaller, lighter, and safer power source in their products.

 

The Company has two product lines. Its Stereax batteries are designed for powering miniature medical implants, industrial wireless sensors and Internet of Things (IoT) applications and the Goliath large format batteries are designed for EV cars and cordless appliances.

 

Through its licensing business model, Ilika supplies its IP portfolio to both OEMs and manufacturing partners in exchange for a license fee and future royalties.

 

About Cirtec Medical‍

 

Cirtec Medical is a global leader in design, development, and manufacturing of complex Class II and III medical devices, specializing inactive implant systems, interventional devices, precision components, and thin film and microelectronics. Since 1987, Cirtec Medical has built extensive in-house capabilities that enable the company to serve as a single-source partner and collaborate with customers to transform their technology into innovative medical devices across a wide array of therapies, including cardiology, neurology, orthopedics and other minimally invasive device applications. Cirtec Medical's deep expertise in precision component design and manufacturing supports every stage of the product lifecycle, ensuring uncompromising quality and performance. With 11 global facilities and a vertically integrated approach, Cirtec Medical aims to expedite time to market, reduce risk, and accelerate revenue generation for our partners. Learn more at CirtecMed.com.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCAKCBQABKDDNK
NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not a registered investment adviser or broker-dealer and does not provide personalized investment advice. Nothing in this record constitutes investment advice or a recommendation to buy, hold, or sell any security. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after consulting an appropriately qualified, licensed financial adviser and reading all relevant offering documentation.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution.

In accordance with the Federal Trade Commission's guidelines on material connections, Proactive Investors discloses the following: we may receive cash or, in some cases, equity compensation from companies whose news is distributed through our platform. This compensation is for news distribution and media services, not for editorial content or coverage decisions. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship does not determine, influence, or shape the editorial content produced. Where we receive equity compensation, such securities are held independently by a third-party broker and sold at the broker's discretion.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

Ilika CEO outlines H1 progress as solid-state batteries advance towards...

Ilika PLC (AIM:IKA, OTCQX:ILIKF) CEO Graeme Purdy talked with Proactive's Stephen Gunnion about progress across its Stereax and Goliath solid-state battery programmes, highlighting upcoming customer deliveries, independent testing and new commercial opportunities. Purdy said qualification of...

13 hours, 2 minutes ago

4 min read